Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 3 | Cancer Cell International

Figure 3

From: Proliferation of Ewing sarcoma cell lines is suppressed by the receptor tyrosine kinase inhibitors gefitinib and vandetanib

Figure 3

Effects on MAPK and PI3K-AKT pathways following treatment with tyrosine kinase inhibitors. Cells were serum starved for 24 hours and then incubated for 1 hour with 10 μM gefitinib or vandetanib. Following this, cells were stimulated with medium containing 10% fetal bovine serum for 4 hours, still in the presence of 10 μM gefitinib or vandetanib. Control cells were treated with vehicle (DMSO) only. Cell extracts were analyzed by western blot using β-actin as a loading control.

Back to article page